RT Journal Article SR Electronic T1 Early detection of prostate gland and breast cancer risk based on routine check-up data using survival analysis trees for left-truncated and right-censored data JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.11.21249491 DO 10.1101/2021.01.11.21249491 A1 Dan Coster A1 Eyal Fisher A1 Shani Shenhar-Tsarfaty A1 Tehillah Menes A1 Shlomo Berliner A1 Ori Rogowski A1 David Zeltser A1 Itzhak Shapira A1 Eran Halperin A1 Saharon Rosset A1 Malka Gorfine A1 Ron Shamir YR 2021 UL http://medrxiv.org/content/early/2021/01/13/2021.01.11.21249491.abstract AB Objective To predict breast cancer (BC) and prostate gland cancer (PGC) risk among healthy individuals by analyzing routine laboratory measurements, vital signs and age.Materials and Methods We analyzed electronic medical records of 20,317 healthy individuals who underwent routine checkups, encompassing more than 600 parameters per visit, and identified those who later developed cancer. We developed a novel ensemble method for risk prediction of multivariate time series data using a random forest model of survival trees for left truncated and right-censored data.Results Using cross-validation, our method predicted future PGC and BC 6 months before diagnosis, achieving an area under the ROC curve of 0.62±0.05 and 0.6±0.03 respectively, better than standard random forest, Cox-regression model and a single survival tree. Our method can complement existing screening tests such as clinical breast examination and mammography for BC, and help in detection of subjects that were missed by these tests.Discussion Computational analysis of results of routine checkups of healthy individuals can improve the detection of those at risk of cancer development.Conclusion Our method may assist in early detection of breast and prostate gland cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported in part by Israel Science Foundation (ISF) grant No. 1339/18 (RS); ISF grant No. 3165/19, within the Israel Precision Medicine Partnership program (RS); grant 2016694 from the US - Israel Binational Science Foundation (BSF), and the US National Science Foundation (NSF) (RS); ELROV grant (S.S.T). D.C. was supported, in part, by fellowships from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University and from Google.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tel-Aviv Sourasky Medical Center Institutional Review Board (Approval no. 02-049-Tlv) - ethical approval was given.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared for ethical/privacy reasons.